Company intelligence / Profile preview

Javelin Medical

Ownership: Private
Development stage: Phase 2

Overview

Javelin Medical is developing Vine™, a first-of-its-kind permanent filter device designed to prevent strokes by intercepting blood clots traveling through the carotid arteries in patients with atrial fibrillation. The device is delivered via a minimally invasive procedure and is currently being evaluated in the CAPTURE II clinical study across several European countries.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically, implantable vascular filter)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Vine

Phase 2

Indications: Stroke prevention in atrial fibrillation

Beyond the preview

Go deeper on Javelin Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Javelin Medical.

Explore the full profile